STIMULUS MDS-US
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 2
- Enrollment
- 39 patients (estimated)
- Sponsors
- Novartis
- Tags
- Hypomethylating Agents (HMA), Monoclonal Antibody
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1389
- NCT Identifier
- NCT04878432
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.